entertainment -WSS

entertainment

author：hotspot 2025-09-30 09:31:13 - browse：6

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

hotspot

WSS

Profiling embryos to choose those with higher IQs is almost a reality

American taxpayers paid $1.8 trillion in health care costs in 2022

Novartis develops a rapidly manufactured CAR

FDA approves first blood sugar monitor without finger pricks

FAMU bans football players from facility after release of rap video shot in team's locker room

What Henrietta Lacks's story taught me about my role as a doctor

hotspot

entertainment

Wikipedia

At least 13 dead in Texas as scorching temps continue

Burning questions about Delta and the next phase of the Covid pandemic

ChatGPT in medicine: STAT answers readers' burning questions

FAMU bans football players from facility after release of rap video shot in team's locker room

Peter Hotez and the public health issue of online harassment

Severe heat forecast: Where scorching temperatures will persist over the next week

Dobbs anniversary: the lost opportunity of abortion as health care

In shift, Texas to cover initial consult for Afghan baby's gene therapy

New air purifier tech could be key to improving indoor air quality

Male doctors called my cancer incurable. A female doctor showed it wasn't

explore

Physician assistants need a new name. Here's what it should be

Medicare Advantage coverage denials need scrutiny, senators say

Allen Institute goes after foundational questions, CEO Costa says

Medicare Advantage overpayments discussion gets experts fired up

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Gene therapy denied for Afghan refugee whose father aided U.S.

focus

hotspot

hotspot

hotspot